| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 7816- | ISQ, | Isoquercitrin Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Gastric Cancer Cells |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | HGC27 |
| 7798- | ISQ, | MOR, | Several targets involved in Alzheimer's disease amyloidogenesis are affected by morin and isoquercitrin |
| - | in-vitro, | AD, | NA |
| 7796- | ISQ, | Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway |
| - | vitro+vivo, | OS, | 143B | - | in-vitro, | OS, | U2OS |
| 7794- | ISQ, | Isoquercitrin induces apoptosis and autophagy in hepatocellular carcinoma cells via AMPK/mTOR/p70S6K signaling pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 7848- | ISQ, | Review of anticancer mechanisms of isoquercitin |
| - | Review, | Var, | NA |
| 2177- | itraC, | Itraconazole improves survival outcomes in patients with colon cancer by inducing autophagic cell death and inhibiting transketolase expression |
| - | Study, | Colon, | NA | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | HCT116 |
| 8011- | itraC, | Anti-proliferation of breast cancer cells with itraconazole: Hedgehog pathway inhibition induces apoptosis and autophagic cell death |
| - | vitro+vivo, | BC, | MCF7 | - | vitro+vivo, | BC, | SkBr3 |
| 8012- | itraC, | Effects and mechanism of itraconazole on prostate cancer PC-3 cell apoptosis |
| - | in-vitro, | Pca, | PC3 |
| 8034- | IVM, | doxoR, | Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation |
| - | in-vitro, | Oral, | NA |
| 8029- | IVM, | Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? |
| - | Review, | Var, | NA |
| 8028- | IVM, | Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential |
| - | Review, | Var, | NA |
| 8025- | IVM, | Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth |
| - | in-vitro, | CRC, | SW480 | - | in-vivo, | CRC, | HCT116 |
| 8024- | IVM, | Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | NE3 |
| 8043- | IVM, | Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE70 | - | in-vitro, | ESCC, | KYSE150 |
| 8039- | IVM, | Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy |
| - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 8045- | IVM, | Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway |
| - | in-vitro, | Cerv, | HeLa |
| 7893- | IVT, | Isovitexin (IV) induces apoptosis and autophagy in liver cancer cells through endoplasmic reticulum stress |
| - | vitro+vivo, | Liver, | NA |
| 7896- | IVT, | VT, | Molecular targets of vitexin and isovitexin in cancer therapy: a critical review |
| - | Review, | Var, | NA |
| 7892- | IVT, | Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway |
| - | in-vitro, | Nor, | HCEC 1CT | - | in-vivo, | Colon, | NA |
| 7965- | JG, | Mechanistic investigation of Juglone (5-hydroxy-1,4-naphthoquinone) as an anti-cancer agent in human colorectal cancer HCT116 and HT-29 cell lines |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 8008- | JG, | Juglone, isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of AR expression in human prostate cancer LNCaP cells |
| - | in-vitro, | Pca, | LNCaP |
| 8007- | JG, | Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis |
| - | in-vitro, | GBM, | U251 |
| 5113- | JG, | Juglone in Oxidative Stress and Cell Signaling |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 5114- | JG, | Juglone, from Juglans mandshruica Maxim, inhibits growth and induces apoptosis in human leukemia cell HL-60 through a reactive oxygen species-dependent mechanism |
| - | in-vitro, | AML, | HL-60 |
| 5115- | JG, | Natural Products to Fight Cancer: A Focus on Juglans regia |
| - | Review, | Var, | NA |
| 1918- | JG, | ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | NA, | NA |
| 1927- | JG, | Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway |
| - | in-vitro, | GC, | SGC-7901 |
| 1926- | JG, | Mechanism of juglone-induced apoptosis of MCF-7 cells by the mitochondrial pathway |
| - | in-vitro, | BC, | MCF7 |
| 1924- | JG, | Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway |
| - | in-vitro, | Lung, | A549 |
| 8090- | KAE, | A systematic review of anti-cancer roles and mechanisms of kaempferol as a natural compound |
| - | Review, | Nor, | NA |
| 8095- | KAE, | Kaempferol: A Key Emphasis to Its Anticancer Potential |
| - | Review, | Var, | NA |
| 8097- | KAE, | The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells |
| - | in-vitro, | CRC, | LS174T |
| 8102- | KAE, | Kaempferol inhibits gastric cancer tumor growth: An in vitro and in vivo study |
| - | vitro+vivo, | GC, | MKN-28 | - | vitro+vivo, | GC, | SGC-7901 | - | in-vitro, | GC, | GES-1 |
| 8105- | KAE, | Chemo-preventive and therapeutic effect of the dietary flavonoid kaempferol: A comprehensive review |
| - | Review, | Var, | NA |
| 8060- | KAE, | Mechanisms underlying apoptosis-inducing effects of Kaempferol in HT-29 human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 8061- | KAE, | Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | OVCAR-3 |
| 8063- | KAE, | Kaempferol exerts anti-proliferative effects on human ovarian cancer cells by inducing apoptosis, G0/G1 cell cycle arrest and modulation of MEK/ERK and STAT3 pathways |
| - | in-vitro, | Ovarian, | NA |
| 8072- | KAE, | Natural defense against colorectal cancer: the effects of kaempferol on epigenetics, apoptosis, inflammation, oxidative stress, and cell proliferation |
| - | Review, | CRC, | NA |
| 8075- | KAE, | QC, | Systematic review on anticancer potential of Kaempferol and quercetin against lung, breast, and colorectal cancers with emphasis on in vitro and in vivo studies |
| - | Review, | Var, | NA |
| 8079- | KAE, | Endoplasmic Reticulum Stress-Mediated Apoptosis Induced by Kaempferol in Colorectal Cancer Cells |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HUH7 | - | in-vitro, | Cerv, | HeLa |
| 8080- | KAE, | Hepatoprotective Effect of Kaempferol—A Review |
| - | Review, | Nor, | NA |
| 8081- | KAE, | The Anticancer Effects and Therapeutic Potential of Kaempferol in Triple-Negative Breast Cancer |
| - | Review, | BC, | NA |
| 9062- | L-THE, | Therapeutic Role of l‑Theanine in Mitigating Cognitive Dysfunction and Neuropathology in Scopolamine-Treated Mice |
| - | in-vivo, | AD, | NA |
| 9064- | L-THE, | L-theanine alleviates myocardial ischemia/reperfusion injury by suppressing oxidative stress and apoptosis through activation of the JAK2/STAT3 pathway in mice |
| - | in-vivo, | Stroke, | NA |
| 9067- | L-THE, | l-Theanine Ameliorates d-Galactose-Induced Brain Damage in Rats via Inhibiting AGE Formation and Regulating Sirtuin1 and BDNF Signaling Pathways |
| - | in-vivo, | AD, | NA |
| 9066- | L-THE, | Chemoprotective effect of theanine in 1,2-dimethylhydrazine-induced colorectal cancer in rats via suppression of inflammatory parameters |
| - | in-vivo, | CRC, | NA |
| 9009- | L-THE, | Therapeutic Role of l-Theanine in Mitigating Cognitive Dysfunction and Neuropathology in Scopolamine-Treated Mice |
| - | in-vivo, | AD, | NA |
| 9007- | L-THE, | L-theanine's therapeutic effects on colorectal cancer: Mechanistic insights from a 1,2-dimethylhydrazine-induced rat model |
| - | in-vivo, | CRC, | NA |
| 9003- | L-THE, | L-Theanine Protects H9C2 Cells from Hydrogen Peroxide-Induced Apoptosis by Enhancing Antioxidant Capability |
| - | in-vitro, | Nor, | H9c2 |
| 8113- | LA, | Analyzing of colorectal cancer related genes and microRNAs expression profiles in response to probiotics Lactobacillus acidophilus and Saccharomyces cerevisiae in colon cancer cell lines |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | SW480 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:42 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid